Sign In
Buy XRAY
DENTSPLY International Earnings Calls
| Release date | May 05, 2026 |
| EPS estimate | $0.280 |
| EPS actual | $0.270 |
| EPS Surprise | -3.57% |
| Revenue estimate | 841.797M |
| Revenue actual | 880M |
| Revenue Surprise | 4.54% |
| Release date | Feb 26, 2026 |
| EPS estimate | $0.280 |
| EPS actual | $0.270 |
| EPS Surprise | -3.57% |
| Revenue estimate | 926.153M |
| Revenue actual | 961M |
| Revenue Surprise | 3.76% |
| Release date | Nov 06, 2025 |
| EPS estimate | $0.450 |
| EPS actual | $0.370 |
| EPS Surprise | -17.78% |
| Revenue estimate | 927.11M |
| Revenue actual | 904M |
| Revenue Surprise | -2.49% |
| Release date | Aug 07, 2025 |
| EPS estimate | $0.500 |
| EPS actual | $0.520 |
| EPS Surprise | 4.00% |
| Revenue estimate | 904.636M |
| Revenue actual | 936M |
| Revenue Surprise | 3.47% |
Last 4 Quarters for DENTSPLY International
Below you can see how XRAY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $13.23 |
| EPS estimate | $0.500 |
| EPS actual | $0.520 |
| EPS surprise | 4.00% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $14.30 |
| Aug 04, 2025 | $14.31 |
| Aug 05, 2025 | $14.05 |
| Aug 06, 2025 | $13.68 |
| Aug 07, 2025 | $13.23 |
| Aug 08, 2025 | $12.96 |
| Aug 11, 2025 | $12.53 |
| Aug 12, 2025 | $13.05 |
| Aug 13, 2025 | $13.85 |
| 4 days before | -7.48% |
| 4 days after | 4.69% |
| On release day | -2.04% |
| Change in period | -3.15% |
| Release date | Nov 06, 2025 |
| Price on release | $11.02 |
| EPS estimate | $0.450 |
| EPS actual | $0.370 |
| EPS surprise | -17.78% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $12.61 |
| Nov 03, 2025 | $12.55 |
| Nov 04, 2025 | $12.49 |
| Nov 05, 2025 | $12.62 |
| Nov 06, 2025 | $11.02 |
| Nov 07, 2025 | $11.18 |
| Nov 10, 2025 | $11.00 |
| Nov 11, 2025 | $10.98 |
| Nov 12, 2025 | $10.84 |
| 4 days before | -12.61% |
| 4 days after | -1.63% |
| On release day | 1.45% |
| Change in period | -14.04% |
| Release date | Feb 26, 2026 |
| Price on release | $12.71 |
| EPS estimate | $0.280 |
| EPS actual | $0.270 |
| EPS surprise | -3.57% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $12.54 |
| Feb 23, 2026 | $12.55 |
| Feb 24, 2026 | $13.14 |
| Feb 25, 2026 | $12.80 |
| Feb 26, 2026 | $12.71 |
| Feb 27, 2026 | $14.68 |
| Mar 02, 2026 | $14.31 |
| Mar 03, 2026 | $13.30 |
| Mar 04, 2026 | $13.44 |
| 4 days before | 1.36% |
| 4 days after | 5.74% |
| On release day | 15.50% |
| Change in period | 7.18% |
| Release date | May 05, 2026 |
| Price on release | $11.37 |
| EPS estimate | $0.280 |
| EPS actual | $0.270 |
| EPS surprise | -3.57% |
| Date | Price |
|---|---|
| Apr 29, 2026 | $11.48 |
| Apr 30, 2026 | $11.75 |
| May 01, 2026 | $11.81 |
| May 04, 2026 | $11.20 |
| May 05, 2026 | $11.37 |
| May 06, 2026 | $11.14 |
| May 07, 2026 | $10.96 |
| May 08, 2026 | $11.00 |
| May 11, 2026 | $10.91 |
| 4 days before | -0.96% |
| 4 days after | -4.05% |
| On release day | -2.02% |
| Change in period | -4.97% |
DENTSPLY International Earnings Call Transcript Summary of Q1 2026
DENTSPLY SIRONA reported Q1 2026 revenue of $880M (as‑reported +0.1%; constant currency -6.7%, or -4.5% adjusting for one‑time items). Adjusted EPS was $0.27 and adjusted EBITDA margin contracted ~430 bps (gross margin headwind ~560 bps) driven by lower volumes, mix and tariff impacts. Management reiterated full‑year 2026 guidance: sales $3.5–$3.6B and adjusted EPS $1.40–$1.50. The company is in early execution of its ‘Return‑to‑Growth’ plan: a commercial restructuring in the U.S., expanded clinical education and sales training, new distributor agreements, and elevated R&D investment. A corporate restructuring is targeted to deliver ~$120M in annual savings with ~ $20M of OpEx savings already realized in Q1; those savings will be reinvested into growth areas. Cash was $190M, operating cash flow improved to $40M, and the company retired ~$79–80M of debt (net debt/EBITDA ~3.3x). Product/innovation highlights include Smart View‑Detect (AI diagnostic aid), new endo systems, and a dental MRI clearance; Wellspect continues steady growth with new product launches. Management expects visibility and benefits from initiatives to build through the year (more meaningful in H2) and into 2027–2028; risks include macro/geopolitical factors, tariffs, and channel destocking in some markets.
